MaxWell Biosystems will exhibit a booth and present posters at the Annual Meeting of the Society for Neuroscience 2017. Where: Walter E. Washington Convention Center, Washington, DC, USA When: 11-15 November 2017
MaxWell Biosystems passes the final stage of Venture Kick and wins CHF 100’000. After presenting at the final stage, MaxWell Biosystems convinced the Venture Kick jury and secured CHF 100’000, in addition to CHF 30’000 already granted in previous stages. Venture Kick supports the first steps of the realization of a business idea and awards selected start-ups with up to CHF 130’000 seed money. The final stage serves as the culmination of the year-long journey of MaxWell Biosystems with Venture Kick. The journey started last July…
MaxWell Biosystems gets more media coverage. ETH Zurich News features the spin-off company MaxWell Biosystems. The article highlights the company’s core technology developed in Hierlemann Lab (D-BSSE) and the motivation to commercialize thanks to the demand of induced pluripotent stem cell boom. Link to English version >> Link to German version >>
The paper by K. Yonehara*, M. Fiscella*, A. Drinnenberg*, et al. entitled “Congenital Nystagmus Gene FRMD7 is necessary for establishing a neuronal circuit asymmetry for direction selectivity” was chosen for the “Best of Neuron” selection 2015-2016. “Best of Neuron“ includes ground-breaking neuroscience research published in Neuron and is a collection of editors’ and readers’ favorites. MaxWell Biosystems HD-MEA core technology was used in this study, to characterize the disease phenotype discovered in the FRMD7 mutant retina. Mutation in the FRMD7 gene is linked to the…
MaxWell Biosystems successfully cleared Venture Kick Stage 2 and received CHF 20,000. See Venture Kick news here >> Venture Kick finances start-ups at the early stage with a grant of up to CHF 130,000 and provides professional support of business experts.
MaxWell Biosystems presented MaxOne at MipTec 2016 in Basel. As one of the events during Basel Life Science Week, over 100 life science companies worldwide gathered at the MipTec International Life Science Exhibition. The MaxWell Biosystems booth was located in the Innovation Village next to other start-up companies. Dr. Michele Fiscella, VP Scientific Affairs, gave daily product presentations on the features and applications of the MaxOne technology.
MaxWell Biosystems exhibited MaxOne and its applications for Cardiac Safety Pharmacology at the 2016 Safety Pharmacology Society (SPS) / Japanese Safety Pharmacology Society (JSPS) / Canadian Society of Pharmacology and Therapeutics (CSPT) Joint Meeting in Vancouver, BC, Canada. The meeting, held from the 18th to 21st of September 2016, had over 568 attendees from around the world, with 253 abstracts presented and 51 exhibiting companies.
MaxWell Biosystems received the ETH spin-off label and joins the strong list of ETH spin-off companies. MaxWell Biosystems continues to be in close collaboration with Prof. Dr. Andreas Hierlemann and the Bio Engineering Laboratory, Department of Biosystems Science and Engineering in Basel.
We are delighted to announce the official registration of MaxWell Biosystems AG in Canton Basel-City, Switzerland. MaxWell Biosystems is now part of Basel’s booming life science and tech start-up community with its close vicinity to multinational biotech and pharmaceutical companies.
MaxWell Biosystems gets through the first round of Venture Kick and receives CHF 10,000 grant. The team will attend the kickers camp on September and then proceed to Stage 2 of the competition, with an opportunity to win an additional CHF 20,000. See the VentureKick news here.